A high percentage of people worldwide are affected by obesity, and we’re not talking about only a cosmetic concern. Obesity is also a medical issue that can lead to serious health problems such as diabetes, heart problems, high blood pressure, and more.
It’s obvious for anybody that the world would sure use more medications for treating obesity. The Danish drugmaker Novo Nordisk has one, and it was approved by the Food and Drug Administration (FDA) on Friday, according to Reuters.
Novo Nordisk’s (NOVOb.CO) semaglutide drug aims to treat obesity
Novo Nordisk’s (NOVOb.CO) is the drug in question. The Danish drugmaker stated that it was expecting the launch of the drug, which would be sold in the US under the name Wegovy.
Doug Langa, who is Novo’s executive vice president for North America operations, declared for Reuters ahead of FDA’s approval:
“There is a huge, huge unmet need here.”
As cited by Fierce Pharma, Langa said that first of all, “we need more patients to seek treatment.” He added that there is “a real stigma and bias” when it comes to obesity, and that “we’ve got too break those walls down.”
It’s also important to help those who struggle with obesity to understand that “it’s not their fault, and that it’s not just about eating less and moving more,” Langa said. “There’s a medical adaptation that they need to understand like any other serious disease.”
The National Institutes of Health reveals that obesity, along with overweight, represent the second leading cause of preventable death in the US.